The company's stock has experienced recent declines, falling 3.7% in a day and 10% over the past month, partly attributed to a negative market reaction to a higher-than-expected inflation report. However, this short-term pullback contrasts with a very strong long-term performance, including a 33.71% one-year return and an approximately 26x return over three years. The company also announced it will present new clinical data on its Signatera test for genitourinary cancers at a major medical symposium.